Mineralys completes enrollment of 261 subjects in pivotal Advance-HTN trial; topline Q1 2025

Mineralys Therapeutics, Inc.

Target enrollment of 261 subjects achieved in Phase 2 Advance-HTN trial of lorundrostat for uncontrolled or resistant hypertension.
Topline data expected Q1 2025; additional subjects in screening may enroll over next several weeks.
Trial is randomized, double-blind, placebo-controlled, add-on to standardized antihypertensive regimen.
Virtual KOL event scheduled for October 30, 2024 to discuss unmet need and clinical program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.